Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2003
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision
Thomas G Roberts, Thomas J Lynch, Bruce A Chabner
The Oncologist
|
June 18, 2002
Choosing chemotherapy for lung cancer based on cost: not yet
Thomas G Roberts, Thomas J Lynch, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer
Rebecca A Miksad, Mithat Gönen, Thomas J Lynch, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 25, 2007
Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities
Asher D Schachter, Marco F Ramoni, Gianluca Baio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2007
Trends in the use and role of biomarkers in phase I oncology trials
Bernardo H L Goulart, Jeffrey W Clark, Homer H Pien, et al.
Chemical Science
|
August 30, 2018
Transfer of photosynthetic NADP<sup>+</sup>/NADPH recycling activity to a porous metal oxide for highly specific, electrochemically-driven organic synthesis
Bhavin Siritanaratkul, Clare F Megarity, Thomas G Roberts, et al.
JAMA
|
November 4, 2004
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
Thomas G Roberts, Bernardo H Goulart, Lee Squitieri, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2003
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision
Thomas G Roberts, Thomas J Lynch, Bruce A Chabner
The Oncologist
|
June 18, 2002
Choosing chemotherapy for lung cancer based on cost: not yet
Thomas G Roberts, Thomas J Lynch, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer
Rebecca A Miksad, Mithat Gönen, Thomas J Lynch, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 25, 2007
Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities
Asher D Schachter, Marco F Ramoni, Gianluca Baio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2007
Trends in the use and role of biomarkers in phase I oncology trials
Bernardo H L Goulart, Jeffrey W Clark, Homer H Pien, et al.
Chemical Science
|
August 30, 2018
Transfer of photosynthetic NADP<sup>+</sup>/NADPH recycling activity to a porous metal oxide for highly specific, electrochemically-driven organic synthesis
Bhavin Siritanaratkul, Clare F Megarity, Thomas G Roberts, et al.
JAMA
|
November 4, 2004
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
Thomas G Roberts, Bernardo H Goulart, Lee Squitieri, et al.
Page
of 2